NCT05402475 is a NA clinical trial of CBT + Mindfulness in Body Dysmorphic Disorder, sponsored by York University.

Who is sponsoring NCT05402475?

NCT05402475 is sponsored by York University.

What drugs are being tested in NCT05402475?

Interventions in NCT05402475: CBT + Mindfulness.

What condition does NCT05402475 study?

NCT05402475 studies Body Dysmorphic Disorder, Body Image Disturbance.

Is NCT05402475 still recruiting?

NCT05402475 is currently status unknown. Last updated 7 July 2023.

Last reviewed 2023-07-07 · How we verify

NCT05402475

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Online Cognitive Behavioural Therapy Intervention for Body Dysmorphic Disorder

Status unknown NA Last updated 7 July 2023

What this trial tests

NA trial testing CBT + Mindfulness in Body Dysmorphic Disorder in 40 participants. Status unknown.

Timeline

1 September 2022

Primary endpoint
1 October 2023

1 November 2023

Quick facts

Lead sponsor	York University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	40
Start date	1 September 2022
Primary completion	1 October 2023
Estimated completion	1 November 2023
Sites	1 location across Canada

Drugs / interventions tested

CBT + Mindfulness

Conditions studied

Body Dysmorphic Disorder — all drugs for Body Dysmorphic Disorder →
Body Image Disturbance — all drugs for Body Image Disturbance →

Sponsor

York University

Who can join

Adults 18 to 55, any sex, with Body Dysmorphic Disorder or Body Image Disturbance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Body Dysmorphic Disorder (BDD) affects 2.3% of the population and is characterized by excessive concerns with imagined or minor defects in physical appearance. Retrospective outcome studies suggest patients affected by BDD don't typically benefit from surgical treatments while cognitive behaviour therapy (CBT) appears to provide symptom - reducing and distress - reducing benefits. Two different 8-week online CBT approaches to assisting individuals with this disorder are compared: one approach will integrate mindfulness meditation methods (in combination with CBT) and one approach will employ CBT methods without reference to mindfulness meditation.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Web-Based Therapist-Guided Mindfulness-Based Cognitive Behavioral Therapy for Body Dysmorphic Disorder: Pilot Randomized Controlled Trial.
Kerry C, Mann P, Babaei N, Katz J, et al · · 2024 · cited 2× · PMID 38865704 · DOI 10.2196/55283

Verify or expand the search:

Other recruiting trials for Body Dysmorphic Disorder

Currently open trials in the same condition.

NCT07036744 — When The Mirror Is Wrong · NA · recruiting
NCT06678295 — Individual Factors of CBT Underlying Success · NA · recruiting
NCT06781853 — CBT for Muscle Dysmorphia and Steroid Abuse: A Randomized Controlled Trial · NA · active not recruiting
NCT04373629 — Perceptual Abnormalities and Their Malleability in BDD · NA · recruiting

Other York University trials

Trials by the same sponsor.

NCT07513987 — IMPACT: Immune and Musculoskeletal Physiological Adaptations to Combined Exercise Training & Nutrition · NA · not yet recruiting
NCT07312409 — Does Taurine Supplementation Improve Vascular Function and Orthostatic Responses in Long COVID? · NA · not yet recruiting
NCT07418320 — Grow Together, Thrive Together: A Feasibility Study of a Brief Relationship Intervention for Emerging Adults and Their C · NA · not yet recruiting
NCT07351630 — Building Blocks for Child and Family Well-being · NA · recruiting
NCT06458933 — Testing Interventions for Borderline Personality Disorder. · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05402475 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by York University
Last refreshed: 7 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05402475.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing